171 related articles for article (PubMed ID: 2550671)
1. Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.
Byrn RA; Sekigawa I; Chamow SM; Johnson JS; Gregory TJ; Capon DJ; Groopman JE
J Virol; 1989 Oct; 63(10):4370-5. PubMed ID: 2550671
[TBL] [Abstract][Full Text] [Related]
2. HIV-infected cells are killed by rCD4-ricin A chain.
Till MA; Ghetie V; Gregory T; Patzer EJ; Porter JP; Uhr JW; Capon DJ; Vitetta ES
Science; 1988 Nov; 242(4882):1166-8. PubMed ID: 2847316
[TBL] [Abstract][Full Text] [Related]
3. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.
McKeating J; Balfe P; Clapham P; Weiss RA
J Virol; 1991 Sep; 65(9):4777-85. PubMed ID: 1870202
[TBL] [Abstract][Full Text] [Related]
4. HIV infection is blocked in vitro by recombinant soluble CD4.
Fisher RA; Bertonis JM; Meier W; Johnson VA; Costopoulos DS; Liu T; Tizard R; Walker BD; Hirsch MS; Schooley RT
Nature; 1988 Jan; 331(6151):76-8. PubMed ID: 2829022
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD4 molecules neutralize human immunodeficiency virus type 1.
Traunecker A; Lüke W; Karjalainen K
Nature; 1988 Jan; 331(6151):84-6. PubMed ID: 2829024
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of SIV infection with soluble receptor molecules.
Allan JS; Strauss J; Buck DW
Science; 1990 Mar; 247(4946):1084-8. PubMed ID: 2309120
[TBL] [Abstract][Full Text] [Related]
7. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.
Lasky LA; Nakamura G; Smith DH; Fennie C; Shimasaki C; Patzer E; Berman P; Gregory T; Capon DJ
Cell; 1987 Sep; 50(6):975-85. PubMed ID: 2441877
[TBL] [Abstract][Full Text] [Related]
8. Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis.
Fenouillet E; Clerget-Raslain B; Gluckman JC; Guétard D; Montagnier L; Bahraoui E
J Exp Med; 1989 Mar; 169(3):807-22. PubMed ID: 2538547
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection.
Weinhold KJ; Lyerly HK; Stanley SD; Austin AA; Matthews TJ; Bolognesi DP
J Immunol; 1989 May; 142(9):3091-7. PubMed ID: 2468713
[TBL] [Abstract][Full Text] [Related]
10. CD4 peptide-protein conjugates, but not recombinant human CD4, bind to recombinant gp120 from the human immunodeficiency virus in the presence of serum from AIDS patients.
Ghetie V; Slaughter C; Wheeler HT; Uhr JW; Vitetta ES
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5690-3. PubMed ID: 2062847
[TBL] [Abstract][Full Text] [Related]
11. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses.
Dey B; Lerner DL; Lusso P; Boyd MR; Elder JH; Berger EA
J Virol; 2000 May; 74(10):4562-9. PubMed ID: 10775592
[TBL] [Abstract][Full Text] [Related]
12. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.
Hussey RE; Richardson NE; Kowalski M; Brown NR; Chang HC; Siliciano RF; Dorfman T; Walker B; Sodroski J; Reinherz EL
Nature; 1988 Jan; 331(6151):78-81. PubMed ID: 2829023
[TBL] [Abstract][Full Text] [Related]
13. CD4+ lymphocyte function with early human immunodeficiency virus infection.
Gurley RJ; Ikeuchi K; Byrn RA; Anderson K; Groopman JE
Proc Natl Acad Sci U S A; 1989 Mar; 86(6):1993-7. PubMed ID: 2564677
[TBL] [Abstract][Full Text] [Related]
14. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
[TBL] [Abstract][Full Text] [Related]
15. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.
Smith DH; Byrn RA; Marsters SA; Gregory T; Groopman JE; Capon DJ
Science; 1987 Dec; 238(4834):1704-7. PubMed ID: 3500514
[TBL] [Abstract][Full Text] [Related]
16. Characterization of CD4 glycoprotein determinant-HIV envelope protein interactions: perspectives for analog and vaccine development.
Farrar WL; Harel-Bellan A; Ferris DK
Crit Rev Immunol; 1988; 8(4):315-39. PubMed ID: 2850890
[TBL] [Abstract][Full Text] [Related]
17. Internal-image anti-idiotype HIV-1gp120 antibody in human immunodeficiency virus 1 (HIV-1)-seropositive individuals with thrombocytopenia.
Karpatkin S; Nardi MA; Kouri YH
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1487-91. PubMed ID: 1741404
[TBL] [Abstract][Full Text] [Related]
18. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase 1 study.
Kahn JO; Allan JD; Hodges TL; Kaplan LD; Arri CJ; Fitch HF; Izu AE; Mordenti J; Sherwin JE; Groopman JE
Ann Intern Med; 1990 Feb; 112(4):254-61. PubMed ID: 2297204
[TBL] [Abstract][Full Text] [Related]
19. Red blood cells bearing CD4 bind to gp120 covered plates and aggregate with cells expressing gp120.
Arvinte T; Schulz B; Madoulet C; Nicolau C
J Acquir Immune Defic Syndr (1988); 1990; 3(11):1041-5. PubMed ID: 1698964
[TBL] [Abstract][Full Text] [Related]
20. A rapid solution immunoassay to quantify binding of the human immunodeficiency virus envelope glycoprotein to soluble CD4.
McQuade TJ; Pitts TW; Tarpley WG
Biochem Biophys Res Commun; 1989 Aug; 163(1):172-6. PubMed ID: 2549987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
